A Study to Validate DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 19-000890
NCT ID: NCT06304168
Sponsor Protocol Number: 19-000890
About this study
The purpose of this study is to validate candidate universal and site-specific methylated DNA markers (MDMs) in DNA extracted from formalin-fixed paraffin embedded primary tumor and control specimens.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria - Aim 1 Tissue:
Cases
- Patient has a biopsy confirmed diagnosis of target histology.
- Tissue samples from synchronous or metachronous primary cancers may be used as long as they are clearly of a different target organ.
- Tumors from patients with an underlying genetic disorder pre-disposing to cancer may be included as long as they are stratified from those without.
Controls
- Patient does not have the diagnosis of target histology.
Exclusion Criteria - Aim 1 Tissue:
- Individuals under 18 years of age.
Cases and Controls:
- Patient has had any transplants prior to tissue collection.
- Patient has received chemotherapy class drugs within 5 years prior to tissue collection.
Cases:
- Patient has had radiation to the current target lesion prior to tissue collection.
- Patient has multi-centric/multi-focal breast cancer with differing genetic profiles (ER/HER2/PR status differ; if multiple masses are present and not all are tested then exclude patient).
- Patient has bilateral breast cancer/DCIS.
Inclusion Criteria - Aim 2 Blood:
Cases
- Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma)
Controls
Exclusion Criteria - Aim 2 Blood:
Cases and Controls
- Patient has known cancer outside of the target cancer 5 years prior to blood collection (not including basal cell or squamous cell skin cancers).
- Patient has had any transplants prior to blood collection.
- Patient has had any prior radiation therapy to the target lesion prior to blood collection.
- Patient has had a biopsy to the target organ and/or lesion within 3 days before blood collection.
Cases
- Patient has had an intervention to completely remove current target pathology.
- The current target pathology is a recurrence.
- Patient has multi-centric/multi-focal breast cancer with differing genetic profiles (ER/HER2/PR status differ; if multiple masses are present and not all are tested then exclude patient).
- Patient has bilateral breast cancer/DCIS.
Inclusion Criteria: Aim 3 Urine
Cases:
- Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma).
Controls:
- Patient does not have a diagnosis of the target histology.
Exclusion Criteria: Aim 3 Urine
- Patient has known cancer outside of the target cancer 5 years prior to urine collection (not including basal cell or squamous cell skin cancers).
- Patient has received chemotherapy class drugs in the 5 years prior to urine collection.
- Patient has had any prior radiation therapy to the target lesion prior to urine collection.
- Patient has had a biopsy to the target organ and/or lesion within 3 days before urine collection.
- The current target pathology is a recurrence.
- Patient has chronic indwelling urinary catheter.
- Patient has had a urinary tract infection within the 14 days prior to sample collection.
- If patient does not have a primary bladder , ureter or urethral cancer, patient has a history of bladder ureter, or urethral cancer.
Cases:
- Patient has had an intervention to completely remove current target pathology.
- The current target pathology is a recurrence.
- Patient has multi-centric/multi-focal breast cancer with differing genetic profiles (ER/HER2/PR status differ; if multiple masses are present and not all are tested then exclude patient).
- Patient has bilateral breast cancer/DCIS.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Eligibility last updated 6/16/23. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
Mayo Clinic Location |
Status |
Contact |
Rochester, Minn.
Mayo Clinic principal investigator John Kisiel, M.D. |
Open for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
More information
Publications
Publications are currently not available